Overview

Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)

Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
In this study, a total of 80 patients with severe coronavirus disease 2019 (COVID-19) infection will be randomized to receive Duvelisib or a placebo. Participants will be enrolled at Emory University Hospital and at the University of Pennsylvania and will be identified and recruited by their treating physician and research team.
Phase:
Phase 2
Details
Lead Sponsor:
Emory University
Collaborators:
University of Pennsylvania
Verastem, Inc.